KRRO KORRO BIO INC

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference.

A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at . Following the presentation, a replay of the event will be available for 30 days.

About Korro

Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Korro Bio Contact Information   

Investor & Media Contact



EN
08/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KORRO BIO INC

 PRESS RELEASE

Korro to Host Virtual Analyst Day on January 27, 2026

Korro to Host Virtual Analyst Day on January 27, 2026 - Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro management team, Bruce Scharschmidt, MD,...

 PRESS RELEASE

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the “Events & Presentations” page ...

 PRESS RELEASE

Korro Reports Third Quarter Financial Results, Provides Updates on KRR...

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- —KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients  —KRRO-110 did not reach projected levels of functional protein following a single administration    —Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026  —Nominated KRRO-121, designed to create a de novo protein variant to activate a biologica...

 PRESS RELEASE

Korro to Participate in Upcoming Investor and Scientific Conferences

Korro to Participate in Upcoming Investor and Scientific Conferences CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September: Citi's 2025 Biopharma Back to School ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, and Loic Vincent, Ph.D., Chief Scientific Officer, will participate in 1x1 investor meetings on Wednesday, September 3, 2025. Cantor Global Healthcare ConferenceDr. Aiyar will pa...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch